Itaconate as a key regulator of respiratory disease

Clin Exp Immunol. 2023 Nov 29:uxad127. doi: 10.1093/cei/uxad127. Online ahead of print.ABSTRACTMacrophage activation results in the accumulation of endogenous metabolites capable of adopting immunomodulatory roles; one such bioactive metabolite is itaconate. After macrophage stimulation, the TCA-cycle intermediate cis-aconitate is converted to itaconate (by aconitate decarboxylase-1, ACOD1) in the mitochondrial matrix. Recent studies have highlighted the potential of targeting itaconate as a therapeutic strategy for lung diseases such as asthma, idiopathic pulmonary fibrosis (IPF), and respiratory infections. This review aims to bring together evidence which highlights a role for itaconate in chronic lung diseases (such as asthma and pulmonary fibrosis) and respiratory infections (such as SARS-CoV-2, influenza and Mycobacterium tuberculosis infection). A better understanding of the role of itaconate in lung disease could pave the way for novel therapeutic interventions and improve patient outcomes in respiratory disorders.PMID:38018224 | DOI:10.1093/cei/uxad127
Source: Clinical and Developmental Immunology - Category: Allergy & Immunology Authors: Source Type: research